Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
- PMID: 23473918
- DOI: 10.1016/j.leukres.2013.01.021
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors
Abstract
Tyrosine kinase inhibitors (TKIs) represent the gold standard therapy of chronic myeloid leukemia and, after being used in imatinib resistant patients, dasatinib and nilotinib are now also used in frontline. In this article, we review data about occurrence of side effects in several trials testing imatinib or second-generation tyrosine kinase inhibitors first line. Literature data about high-dose imatinib used front-line as single treatment or with different combinations is also examined. A literature search for relevant studies was undertaken mainly in PubMed. This review is aimed to summarize the safety of different treatments and to discuss the current management of most common side effects. Literature evidence supports the fact that side effects associated to TKIs seem to differ between agents, but most of side effects reported occur early within the treatment course. Second generation frontline TKIs reduce the incidence of most of side effects reported with imatinib and peculiar events observed are typically manageable through drug dose reduction or treatment interruption.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
-
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005. Clin Ther. 2007. PMID: 18158072 Review.
-
[Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].Rinsho Ketsueki. 2014 Jan;55(1):130-2. Rinsho Ketsueki. 2014. PMID: 24492046 Japanese.
-
Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.Ther Drug Monit. 2010 Dec;32(6):680-7. doi: 10.1097/FTD.0b013e3181f4d9c5. Ther Drug Monit. 2010. PMID: 20864900 Review.
-
Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia.Clin Lymphoma Myeloma Leuk. 2010 Oct;10(5):331-5. doi: 10.3816/CLML.2010.n.065. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21030345 Review.
-
The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.Expert Opin Pharmacother. 2011 Sep;12(13):2075-87. doi: 10.1517/14656566.2011.597741. Epub 2011 Jul 1. Expert Opin Pharmacother. 2011. PMID: 21721847 Review.
Cited by
-
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Leukemia. 2015 May;29(5):1123-32. doi: 10.1038/leu.2015.36. Epub 2015 Feb 13. Leukemia. 2015. PMID: 25676422 Clinical Trial.
-
Cardiac complications of cancer therapies.Adv Cancer Res. 2022;155:167-214. doi: 10.1016/bs.acr.2022.03.006. Epub 2022 Apr 20. Adv Cancer Res. 2022. PMID: 35779874 Free PMC article.
-
The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in mice.PLoS One. 2017 Oct 5;12(10):e0185704. doi: 10.1371/journal.pone.0185704. eCollection 2017. PLoS One. 2017. PMID: 28982129 Free PMC article.
-
Killing two birds with one stone: a case of GIST and supervening CML.BMJ Case Rep. 2015 Oct 14;2015:bcr2015211698. doi: 10.1136/bcr-2015-211698. BMJ Case Rep. 2015. PMID: 26468222 Free PMC article.
-
Clinical pathway for patients with Chronic Myeloid Leukaemia: The Euriclea Project.Acta Biomed. 2017 Jul 18;88(3S):5-12. doi: 10.23750/abm.v88i3-S.6608. Acta Biomed. 2017. PMID: 28752827 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
